Hospital

Nakia Eldridge, PharmD, MBA, shares insights for health system and community pharmacists attending the 2025 APhA Annual Meeting & Exposition.

Patients with central nervous system (CNS) involvement achieved favorable outcomes with chimeric antigen receptor (CAR) T-cell therapy.

Non-high-density lipoprotein cholesterol was found to be more effective at predicting cardiovascular events such as stroke, myocardial outcomes, heart failure, and others compared with low-density lipoprotein cholesterol.

Sjögren's disease is one of the most common chronic autoimmune diseases that affects 4 million individuals around the world.

This subset of heart failure requires unique therapeutic considerations.

Vutrisiran becomes the first and only therapeutic FDA-approved to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.

The agent is the only approved therapy designed to address the underlying mechanisms of the disease.

Health care professionals in the study found it challenging to manage the complexities of disordered eating in patients with type 1 diabetes alongside their other responsibilities.

Allogeneic stem cell transplant (allo-SCT) conditioning with busulfan/fludarabine with thiotepa and posttransplant cyclophosphamide induced improved 2-year progression-free survival and overall survival in patients with myelofibrosis, especially older adults.

BeeR is a bacterial protein from the family Verrucomicrobiota that influences cell shape and division.

As HIV treatment and prevention evolve, the use of long-acting injectables and their role in combating the HIV epidemic grows.

Prioritizing preventive measures for high-risk individuals would effectively address half of RSV hospitalizations.

The combination was approved for treatment of patients with gastroesophageal junction (GEJ) adenocarcinoma.

Ononogbu discusses research, health equity, and sickle cell advancements.

Reducing the dose of ibrutinib following adverse events improved tolerability without compromising clinical efficacy in chronic lymphocytic leukemia (CLL).

The findings extend prior data underscoring the clinical benefit of the agent and its place in global clinical practice guidelines.

As indicated by prior literature, a second dose of intravenous immunoglobulin (IVIG) in patients with Guillain-Barré syndrome increases serum immunoglobulin G levels without improving clinical outcomes.

Factor XI inhibitors show promise as a safer alternative to direct oral anticoagulants for preventing and treating thrombosis, offering similar efficacy with reduced bleeding risk.

Sharita Howe, PharmD, discusses her recent acknowledgement by MM+M, who acknowledged her as a part of the next wave of health care leaders in their recognition of 40 under 40 leaders in health care.

Pharmacists can optimize management of this condition with intravenous iron therapy guidance.

A phase 2 study showed that elotuzumab combined with pomalidomide, bortezomib, and dexamethasone was safe and efficacious.

The 3CL protease inhibitor is designed to suppress the replication of SARS-CoV-2, preventing COVID-19 illness, even if a household member is infected.

The patient is the first to be cured using lovotibeglogene autotemcel, a novel cell-based gene therapy.

In this retrospective study, investigators evaluated a pharmacy-led initiative in the emergency department (ED), finding a potential reduction in ED revisits and hospital readmissions, though results were not statistically significant.

The new indication would include adults with heart failure with a left ventricular ejection fraction (LVEF) of 40% or higher, such as mildly reduced or preserved LVEF.

Although RSV has long been associated with infants and young children, research demonstrates that it is also a significant health risk for adults over the age of 60.

Treatment with ruxolitinib in patients with myelofibrosis and anemia was associated with more inpatient medical center and emergency department visits while increasing health care-related financial burdens compared with nonanemic patients.

Tarlatamab was approved by the FDA in May 2024 for patients who progressed after platinum-based chemotherapy.

This marks steps toward improving health care pricing transparency, but further reforms are needed to reduce costs long-term.

Lipid metabolism plays a critical role in the function of T-cells.